Quantitation of the immunological adjuvants, monophosphoryl lipid A and Quil A in poly (lactic-co-glycolic acid) nanoparticles using high performance liquid chromatography with evaporative light scattering detection

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 975, Issue , 2015, Pages 45-51

  Bobbala, Sharan ^a   McDowell, Arlene ^a   Hook, Sarah ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adjuvants; ELSD; Encapsulation efficiency; In vitro release; Nanoparticles; Validation

Indexed keywords

COPOLYMERS; ENCAPSULATION; LIGHT SCATTERING; LIQUIDS; NANOPARTICLES; PARTICLE SIZE; VACCINES;

ADJUVANTS; ELSD; ENCAPSULATION EFFICIENCY; IN-VITRO; VALIDATION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACETONITRILE; FORMIC ACID; METHANOL; NANOPARTICLE; PHOSPHORYL LIPID A; POLYGLACTIN; QUIL A; WATER; IMMUNOLOGICAL ADJUVANT; LACTIC ACID; LIPID A; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; QUILLAJA SAPONIN;

ANALYTIC METHOD; ARTICLE; CALIBRATION; ELUTION; EVAPORATIVE LIGHT SCATTERING DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEASUREMENT ACCURACY; NANOENCAPSULATION; NEBULIZER; PARTICLE SIZE; PRESSURE; QUANTITATIVE ANALYSIS; TEMPERATURE; VALIDATION STUDY; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG RELEASE; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG LIBERATION; LACTIC ACID; LIMIT OF DETECTION; LIPID A; NANOPARTICLES; POLYGLYCOLIC ACID; QUILLAJA SAPONINS;

EID: 84912036328     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2014.11.006     Document Type: Article

References (30)

1. Wack A., Rappuoli R. Vaccinology at the beginning of the 21st century. Curr. Opin. Immunol. 2005, 17:411-418.
2. Edelman R. Survey of human-use adjuvants. Exp. Rev. Vaccines 2003, 2:167-188.
3. Baldridge J.R., Crane R.T. Monophosphoryl Lipid A (MPL) Formulations for the Next Generation of Vaccines. Methods 1999, 19:103-107.
4. Baldridge J.R., McGowan P., Evans J.T., Cluff C., Mossman S., Johnson D., Persing D. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Exp. Opin. Biol. Therap. 2004, 4:1129-1138.
5. Kensil C., Wu J.-Y., Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Vaccine Design 1995, 525-541. Springer, US. M. Powell, M. Newman (Eds.).
6. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 1999, 17:1075-1081.
7. Demana P.H., Fehske C., White K., Rades T., Hook S. Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes. Immunol. Cell. Biol. 2004, 82:547-554.
8. Mikloska Z., Rückholdt M., Ghadiminejad I., Dunckley H., Denis M., Cunningham A.L. Monophosphoryl Lipid A and QS21 Increase CD8 T Lymphocyte Cytotoxicity to Herpes Simplex Virus-2 Infected Cell Proteins 4 and 27 Through IFN-γ and IL-12 Production. J. Immunol. 2000, 164:5167-5176.
9. Rattanapak T., Young K., Rades T., Hook S. Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration. J. Pharm. Pharmacol. 2012, 64:1560-1569.
10. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Rel. 2012, 161:505-522.
11. Makadia H.K., Siegel S.J. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers 2011, 3:1377-1397.
12. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol. 2004, 82:506-516.
13. Foged C., Sundblad A., Hovgaard L. Targeting Vaccines to Dendritic Cells. Pharm. Res. 2002, 19:229-238.
14. Qureshi N., Takayama K., Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem. 1982, 257:11808-11815.
15. Qureshi N., Mascagni P., Ribi E., Takayama K. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J. Biol. Chem. 1985, 260:5271-5278.
16. Hagen S.R., Thompson J.D., Snyder D.S., Myers K.R. Analysis of a monophosphoryl lipid A immunostimulant preparation from Salmonella minnesota R595 by high-performance liquid chromatography. J. Chromatogr. A 1997, 767:53-61.
17. Santos W.R., de Lima V.M.F., de Souza E.P., Bernardo R.R., Palatnik M., de Sousa C.B.P. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 2002, 21:30-43.
18. Dobrovolskaia M.A., Neun B.W., Clogston J.D., Ding H., Ljubimova J., McNeil S.E. Ambiguities in applying traditional Limulus Amebocyte Lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine 2010, 5:555-562.
19. Hamdy S., Haddadi A., Somayaji V., Ruan D., Samuel J. Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (D,L-lactic-co-glycolic acid) nanoparticle formulations. J. Pharmaceut. Biomed. Anal. 2007, 44:914-923.
20. Pham H.L., Ross B.P., McGeary R.P., Shaw P.N., Davies N.M. Synthesis of cationic derivatives of Quil A and the preparation of cationic immune-stimulating complexes (ISCOMs). Int. J. Pharmaceut. 2009, 376:123-133.
21. Agblevor F., Hames B., Schell D., Chum H. Analysis of biomass sugars using a novel HPLC method. Appl. Biochem. Biotechnol. 2007, 136:309-326.
22. Nogueira L.C., Silva F., Ferreira I.M.P.L.V.O., Trugo L.C. Separation and quantification of beer carbohydrates by high-performance liquid chromatography with evaporative light scattering detection. J. Chromatogr. A 2005, 1065:207-210.
23. Alsaadi M.M., Christine Carter K., Mullen A.B. High performance liquid chromatography with evaporative light scattering detection for the characterisation of a vesicular delivery system during stability studies. J. Chromatogr. A 2013, 1320:80-85.
24. Hamdy S., Molavi O., Ma Z., Haddadi A., Alshamsan A., Gobti Z., Elhasi S., Samuel J., Lavasanifar A. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008, 26:5046-5057.
25. Stittelaar K.J., Boes J., Kersten G.F.A., Spiekstra A., Mulder P.G.H., de Vries P., Roholl P.J.M., Dalsgaard K., van den Dobbelsteen G., van Alphen L., Osterhaus A.D.M.E. In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine 2000, 18:2482-2493.
26. Hopkins M., Lees B.G., Richardson D.G., Woroniecki S.R., Wheeler A.W. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL). Allergol. Immunopath. 2001, 29:245-254.
27. Newman K.D., Samuel J., Kwon G. Ovalbumin peptide encapsulated in Poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J. Control. Release 1998, 54:49-59.
28. Ramchandani M., Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J. Control. Release 1998, 54:167-175.
29. Faisant N., Siepmann J., Benoit J.P. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur. J. Pharmaceut. Sci. 2002, 15:355-366.
30. Persing D.H., Coler R.N., Lacy M.J., Johnson D.A., Baldridge J.R., Hershberg R.M., Reed S.G. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 2002, 10:s32-s37.